Glatiramer

 

Topic mentions per year

Topic mentions per year

1999-2017
012319992017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Patients received cranial-irradiation can be affected with cognitive deficits and decreasing hippocampal neurogenesis. In this… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
OBJECTIVES Metabolic flexibility is defined as ability to adjust fuel oxidation to fuel availability. Multiple sclerosis (MS… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 5
Is this relevant?
2011
2011
Oral drugs for relapsing–remitting multiple sclerosis (RRMS) have been recently investigated and, one of these, fingolimod, is… (More)
  • figure 5
  • figure 1
  • figure 2
  • figure 3
  • figure 2
Is this relevant?
2010
2010
OBJECTIVE To summarize major clinical trials which evaluate the efficacy and safety data of approved disease modifying agents for… (More)
  • table 1
Is this relevant?
2009
2009
BACKGROUND Osteoporosis is a complication of multiple sclerosis (MS), especially if corticosteroid therapy is given. Little is… (More)
  • figure 1
  • table 1
Is this relevant?
2007
2007
BACKGROUND In 1993, interferon beta-1b became the first of 4 self-injectable multiple sclerosis (MS) drugs to be approved by the… (More)
Is this relevant?
2005
2005
BACKGROUND Glatiramer acetate therapy is thought to be effective for multiple sclerosis (MS) by promoting T(H)2 cytokine… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2004
2004
$ 50%, and glatiramer did not modify this effect. When infected cells were exposed to ampicillin for 24 h after phagocytosis, the… (More)
Is this relevant?
Review
2003
Review
2003
Glatiramer acetate (GA) (Copaxone(R)) is a worldwide-approved drug for the treatment of relapsing multiple sclerosis (MS), an… (More)
Is this relevant?
1999
1999
BACKGROUND Glatiramer acetate (Copaxone) therapy reduces clinical disease activity in relapsing-remitting multiple sclerosis (MS… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?